BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 12373354)

  • 21. Thrombopoietin serum levels at the start of mobilization, collection, and transfusion of autologous peripheral blood stem cells.
    Bojko P; Nowak N; Moritz T; Flasshove M; Harstrick A; Seeber S
    J Clin Apher; 1999; 14(2):57-62. PubMed ID: 10440940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation.
    Singhal S; Powles R; Kulkarni S; Treleaven J; Sirohi B; Millar B; Shepherd V; Saso R; Rowland A; Long S; Cabral S; Horton C; Mehta J
    Bone Marrow Transplant; 2000 Mar; 25(5):501-5. PubMed ID: 10713626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD34+ cell dose and CD33- subsets: collection and engraftment kinetics in autologous peripheral blood stem cells transplantation.
    Sampol Mayol A; Besalduch Vital J; Galmés Llodrá A; Bargay Lleonart J; Matamoros Flori N; Morey Sureda M; Novo García A; Mascaró Riera M; Gonzaléz Bach E; Martínez García P
    Haematologica; 1998 Jun; 83(6):489-95. PubMed ID: 9676020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Appropriate timing of G-CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT.
    Xu L; Chang C; Li X; Gan W
    J Clin Apher; 2009; 24(6):232-7. PubMed ID: 19899124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Peripheral blood stem cell mobilisation by granulocyte-colony stimulating factor in patients with acute and old myocardial infarction for intracoronary cell infusion.
    Chang SA; Kang HJ; Lee HY; Kim KH; Hur J; Han KS; Park YB; Kim HS
    Heart; 2009 Aug; 95(16):1326-30. PubMed ID: 19460773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delayed introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: retrospective study of 45 cases.
    Dolgopolov I; Andreeva L; Yankelevich M; Mscheidze D; Siegel S; Mentkevich G
    Am J Hematol; 2003 Aug; 73(4):225-9. PubMed ID: 12879423
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
    Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
    Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
    Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
    Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
    Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
    Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
    Kopf B; De Giorgi U; Vertogen B; Monti G; Molinari A; Turci D; Dazzi C; Leoni M; Tienghi A; Cariello A; Argnani M; Frassineti L; Scarpi E; Rosti G; Marangolo M
    Bone Marrow Transplant; 2006 Sep; 38(6):407-12. PubMed ID: 16951690
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Middle-high dose of cyclophosphamide or conventional routine chemotherapy with increased dose of cyclophosphamide combined with G-CSF for mobilizing peripheral blood progenitor cells in patients with tumor].
    Lu DP; Liu KY; Guo NL; Shi YK; He XH; Lou FD; Da WM; Zhang BL; Wang LX; Ke XY
    Zhonghua Xue Ye Xue Za Zhi; 2003 Feb; 24(2):68-70. PubMed ID: 12697098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD34+ cell adhesion molecule profiles differ between patients mobilized with granulocyte-colony-stimulating factor alone and chemotherapy followed by granulocyte-colony-stimulating factor.
    Ford CD; Greenwood J; Anderson J; Snow G; Petersen FB
    Transfusion; 2006 Feb; 46(2):193-8. PubMed ID: 16441594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma.
    Fruehauf S; Klaus J; Huesing J; Veldwijk MR; Buss EC; Topaly J; Seeger T; Zeller LW; Moehler T; Ho AD; Goldschmidt H
    Bone Marrow Transplant; 2007 Jun; 39(12):743-50. PubMed ID: 17450182
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind low dose-finding phase II study of granulocyte colony-stimulating factor combined with chemotherapy for stem cell mobilization in patients with non-Hodgkin's lymphoma.
    Lefrère F; Zohar S; Bresson JL; Chevret S; Mogenet A; Audat F; Durand-Zaleski I; Ghez D; Dal Cortivo L; Piesvaux P; Cavazzana-Calvo M; Varet B
    Haematologica; 2006 Apr; 91(4):550-3. PubMed ID: 16585020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
    Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
    Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF.
    Ozcelik T; Topcuoglu P; Beksac M; Ozcan M; Arat M; Biyikli Z; Bakanay SM; Ilhan O; Gurman G; Arslan O; Demirer T
    Bone Marrow Transplant; 2009 Dec; 44(12):779-83. PubMed ID: 19597420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management strategies for poor peripheral blood stem cell mobilization.
    Moog R
    Transfus Apher Sci; 2008 Jun; 38(3):229-36. PubMed ID: 18485822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive parameters for granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization.
    Okano A; Ashihara E; Shimazaki C; Uchiyama H; Inaba T; Taniguchi K; Maekawa T; Taniwaki M
    J Clin Apher; 2008; 23(6):171-7. PubMed ID: 18988229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte-colony stimulating factor.
    Shimazaki C; Oku N; Ashihara E; Okawa K; Goto H; Inaba T; Ito K; Fujita N; Tsuji H; Murakami S
    Bone Marrow Transplant; 1992 Oct; 10(4):341-6. PubMed ID: 1384902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
    Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
    Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.